SCHEMBL15344010

SCHEMBL15344010

COCCCCCCCCCCC1=C(C)C(=O)C(OC)=C(OC)C1=O

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.73
TDP1 Q9NUW8 2/20 0.73
ALDH1A1 P00352 1/20 0.73
THRB P10828 1/20 0.73
LMNA P02545 1/20 0.71
PGR P06401 1/20 0.71
CYP3A4 P08684 1/20 0.71
CYP2D6 P10635 1/20 0.71
CYP2C9 P11712 1/20 0.71
MAOA P21397 1/20 0.71
TBXA2R P21731 1/20 0.71
MAPK1 P28482 1/20 0.71
AVPR2 P30518 1/20 0.71
CYP2C19 P33261 1/20 0.71
HTR2B P41595 1/20 0.71
HTT P42858 1/20 0.71
PDE3A Q14432 1/20 0.71
SIRT2 Q8IXJ6 1/20 0.71
SLC29A1 Q99808 1/20 0.71
TRAP1 Q12931 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15695725 0.98 MAPT (0.70) MAPTTDP1ALDH1A1THRBLMNA
SCHEMBL19932691 0.87 MAPT (0.69) MAPTTDP1ALDH1A1THRBLMNA
SCHEMBL21026409 0.87 MAPT (0.69) MAPTTDP1ALDH1A1THRBLMNA
SCHEMBL7366956 0.85 IDO1 (0.62) MAPTTDP1ALDH1A1THRBLMNA
SCHEMBL15369106 0.85 MAPT (0.71) MAPTTDP1ALDH1A1THRBLMNA
SCHEMBL22157909 0.85 MAPT (0.69) MAPTTDP1ALDH1A1THRBLMNA
SCHEMBL29200204 0.85 MAPT (0.64) MAPTTDP1ALDH1A1THRBLMNA
SCHEMBL29200203 0.85 MAPT (0.61) MAPTTDP1ALDH1A1THRBLMNA
SCHEMBL23888071 0.84 MAPT (1.00) MAPTTDP1ALDH1A1THRBLMNA
SCHEMBL11853848 0.84 MAPT (1.00) MAPTTDP1ALDH1A1THRBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150025006-A1 Pharmaceutical Combinations Including Anti-Inflammatory and Antioxidant Conjugates Useful for Treating Metabolic Disorders GENMEDICA THERAPEUTICS SL (ES) 2015-01-22 US disclosed
US-8575217-B2 Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders GENMEDICA THERAPEUTICS SL (ES) 2013-11-05 US disclosed
US-20130281520-A1 Anti-Inflammatory And Antioxidant Conjugates Useful For Treating Metabolic Disorders GENMEDICA THERAPEUTICS SL (ES) 2013-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130281520-A1 Anti-Inflammatory And Antioxidant Conjugates Useful For Treating Metabolic Disorders HSD17B14, SORD, GPX4 MAPT 3367/4885TDP1 3117/4885ALDH1A1 160/4885
US-20150025006-A1 Pharmaceutical Combinations Including Anti-Inflammatory and Antioxidant Conjugates Useful for Treating Metabolic Disorders IAPP, AMY2A, GPR119 MAPT 3542/4885TDP1 2113/4885ALDH1A1 739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.